A Phase II Study of Hu1D10 in Recurrent Hodgkin's Disease
- Determine the response rate of patients with recurrent Hodgkin's lymphoma treated with
monoclonal antibody Hu1D10.
- Determine the duration of response and progression-free survival of patients treated
with this drug.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive monoclonal antibody Hu1D10 IV over 2 hours. Treatment repeats weekly for a
total of 4 doses in the absence of disease progression or unacceptable toxicity.
Patients are followed at weeks 5 and 8 and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study within
approximately 12 months.
Masking: Open Label, Primary Purpose: Treatment
Sandra J. Horning, MD
United States: Federal Government
|Stanford University Medical Center||Stanford, California 94305-5408|